Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  degarelix
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-22 of 22 for your search:
Start Over
Firmagon (Degarelix) Intermittent Therapy
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: CURC - FIT-0002, NCT01512472
Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms
Phase: Phase III, Phase II
Type: Treatment
Status: Approved-not yet active
Age: 22 and over
Sponsor: Other
Protocol IDs: ANDA208414, FWA00015357, IORG0007849, IRB00009424, IND78420, NPI1831468511, NPI1023387701, NCT02403505
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: RTOG-0924, CDR0000701128, NCI-2011-02674, NCT01368588
High-Dose Brachytherapy in Treating Patients With Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: PROS0065, NCI-2015-00089, P30CA124435, NCT02346253
Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy
Phase: Phase II
Type: Treatment
Status: Active
Age: 40 to 80
Sponsor: Other
Protocol IDs: H11-08172, NCT01446991
Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: BCCA_Deg01, NCT01630967
Degarelix Neo-Adjuvant Radical Prostatectomy Trial
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: DEG_PRE-OP_001, Degarelix Pre-Op, NCT01674270
Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2012-0993, NCI-2013-00460, NCT01786265
Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EMT13001, NCT01990196
Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: UC-0160/1204, NCT01994239
TRial on the Endocrine Activity of Neoadjuvant Degarelix
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IBCSG 41-13, 2012-005326-29, NCT02005887
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C27003, U1111-1152-9537, 2013-005002-53, NCT02135445
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Status: Approved-not yet active
Age: 19 and over
Sponsor: Other
Protocol IDs: 14-0909.cc, NCI-2014-02219, NCT02278185
Studying the Effects of Olaparib Given to Men With Intermediate/High Risk Prostate Cancer Before Radical Prostatectomy
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: CaNCaP03, 2014-004417-86, NCT02324998
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Phase: No phase specified
Type: Natural history/Epidemiology
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CMX-DELAY2010, NCT01366053
Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-182, NCT01542021
Treatment of Prostate Cancer With Firmagon®
Phase: No phase specified
Type: Natural history/Epidemiology
Status: Active
Age: 18 to 95
Sponsor: Other
Protocol IDs: UCM12-01, NCT01710098
Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 7846, NCI-2012-02136, P30CA015704, NCT01731912
Degarelix Before Radical Prostatectomy
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: 11/H0311/2, NCT01852864
Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina
Phase: No phase specified
Type: Natural history/Epidemiology
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 000036, NCT01861236
Start Over